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Abstract:  Patients with mechanical valve prostheses require a lifelong anticoagulant treatment. The combined use of 
Warfarin and low-dose aspirin appears to reduce the risk of valve thrombosis and systemic embolism at a low risk of bleeding.  
The management of women with prosthetic heart valves during pregnancy poses a particular challenge, as there are no 
available controlled clinical trials to provide guidelines for effective antithrombotic therapy. Oral anticoagulants, such as 
Warfarin, cause foetal embryopathy; unfractionated heparin and low-molecular-weight heparin have been reported to be 
ineffective in preventing thromboembolic complications. This article discusses the available data and the most recent 
guidelines in the antithrombotic management of patients with prosthetic valves, and antithrombotic therapy in various clinical 
situations such as pregnant women with prosthetic heart valves, and patients with prosthetic heart valves undergoing 
noncardiac surgery. 
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Introduction 
Patients with mechanical valve prosthesis, require long-
term anticoagulation and aspirin administration because of 
the risk of thromboembolism, which is often greatest in 
the first postoperative year. Without anticoagulants and 
aspirin, the incidence of thromboembolism is three-to six-
fold higher than when proper doses of these medications 
are administered [1]. 
 
Abnormal flow conditions imposed by the prosthetic 
heart valves increase risk of thrombosis and embolism. 
The abnormal flow conditions caused by prosthetic valves 
are of two types: relative stagnation and high-velocity 
disturbed flow causing high shear stress [2]. Aortic valve 
prostheses are associated with high-velocity flow, high 
shear stress and relatively little stagnation. In contrast, 
mitral valve prostheses are associated with much more 
stagnation because the velocity of forward flow is much 
lower, and they are situated facing into the left atrium, 
which is an area of relative stagnation. These fundamental 
differences result in a higher incidence of both valve 
thrombosis and embolism after mitral valve replacement 
(MVR) than after aortic valve replacement (AVR) [2]. 
 
Despite design changes and modifications that have 
been made to improve the longevity, hemodynamics, and 
thrombogenicity of newer generation mechanical valves, 
thromboembolism and anticoagulant-related bleeding 
continue to account for 75% of all complications after 
mechanical valve replacement [3]. 
 
Antithrombotic management following valve 
replacement 
Current practice suggests that Warfarin therapy should 
begin about 2 days after prosthetic valve placement [3,5]. 
 
After mechanical AVR, the goal of antithrombotic 
therapy is usually to achieve an International Normalized 
Ratio (INR) of 2.5 to 3.5 for the first 3 months after 
surgery and 2.0 to 3.0 beyond that time [4]. Low-dose 
aspirin (75 to 100 mg per day) is also indicated in addition 
to Warfarin [6]. At that level of anticoagulation, the risk of 
significant haemorrhage appears to be 1% to 2% per 
year. 
 
Thrombosis and thromboembolism risks are greater with 
any mechanical valves in the mitral than the aortic 
position, and, therefore, higher INR levels (2.5 to 3.5) are 
generally recommended for mechanical mitral valve 
prostheses. 
 
Homografts and most bioprosthetic valves in the aortic 
position do not require long-term anticoagulation, 
providing that the patient is in sinus rhythm and has 
adequate left ventricular systolic function. However, there 
is evidence that anticoagulant therapy for the first 3 
months, until the sewing ring is endothelialized, reduces 
the higher incidence of embolism at this time. After 3 
months, the tissue valve can be treated like native valve, 
and Warfarin can be discontinued in more than two thirds 
of patients with biological valves.  In the remaining 
patients, who have risk factors for thromboembolism 
(table 1), lifelong Warfarin therapy, to achieve an INR of 
2.0 to 3.0, is indicated [5,7,8].  
 
Antiplatelet agents without anticoagulants do not 
provide adequate protection to patients with mechanical 
valve prosthesis. However, the addition of aspirin, 80 to 
160 mg daily, together with Warfarin may reduce the risk 
of thromboembolism and should be given to all patients 
with mechanical prosthetic valves [4,8]. 
 
Aspirin alone has been recommended as long-term 
prophylaxis for patients with bioprostheses to minimize 
platelet adhesion. 
Clopidogrel (Plavix) may be considered for those who 
cannot take aspirin [4]. 
 
Risk factors for thrombosis (Table 1), and underlying 
causes of hypercoagulability should be corrected if 
possible. Atrial fibrillation is associated with a fivefold 
increase in the risk of stroke and, therefore, it is important 
to try to restore sinus rhythm. Hypertension, obesity, and 
hyperlipidemia should be treated, cigarette smoking 
stopped, and advice is given about diet, exercise and the 
avoidance of potentially thrombogenic drugs. Correcting 
these factors will substantially reduce the risk of 
thrombosis. 
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Table 1  Risk Factors for Prosthetic Valve Thrombosis 
1- Atrial fibrillation. 
2- Previous thromboembolism. 
3- Left ventricular dysfunction (LVEF < 30%). 
4- Mechanical mitral or tricuspid prosthesis. 
5- Older-generation thrombogenic valves (e.g. Starr-Edwards, 
and mechanical disc valves). 
6-Those with demonstrated thrombotic problems when 
previously off Warfarin therapy. 
7- More than one mechanical valves. 
8- Hypercoagulable state. 
 
Table 2 Potential Advantages of LMWHs over UFH during 
pregnancy 
1- Cause less heparin-induced thrombocytopenia; 
2- Have a longer plasma half-life & a more predictable dose 
response; 
3- Easier to administer, with lack of need for laboratory 
monitoring; 
4- Associated with a lower risk of heparin-induced 
osteoporosis; 
5- Appear to have a low risk of bleeding complications. 
 
Table 3 Recommended therapeutic interventions in patients with 
prosthetic valves who suffered an embolic event while receiving 
adequate antithrombotic therapy. 
Current 
Therapy 
Current 
INR range 
Intervention to prevent 
further embolic events 
Warfarin    2.0-3.0 
Increase Warfarin dose to 
achieve INR of 2.5-3.5 
Warfarin    2.5-3.5 
Increase Warfarin dose to 
achieve INR of 3.5-4.5 
Not taking 
ASA 
 
Add ASA 75 to 100 mg per 
day. 
Warfarin 
plus ASA  
75-100 
mg/day 
 
Increase ASA to 325 mg 
daily. 
Aspirin 
alone 
 
Increase ASA to 325 
mg/day, add Clopidogrel 
75 mg/day and/or add 
Warfarin. 
 
 
In the patient who has a definite embolic episode while 
undergoing adequate antithrombotic therapy, the dosage 
of antithrombotic therapy should be increased, when 
clinically safe (Table 3) [4]. 
 
In patients with mechanical valve prostheses who have 
experienced repeated systemic embolization despite 
optimal anticoagulation therapy, the incidence of 
embolization might be reduced by replacement with a 
tissue (bioprosthetic) valve.  
 
The risk of thrombosis of mechanical prostheses in the 
tricuspid valve position is quite high and, therefore, 
bioprostheses are preferred at this site [9]. 
 
It must be recognized that the administration of 
Warfarin carries its own mortality and morbidity, i.e., 
serious haemorrhage. 
 
Interruption of Warfarin therapy for invasive 
procedures or noncardiac surgery 
Anticoagulation interruption in a patient with a 
prosthetic valve is potentially hazardous and may result in 
prosthetic valve thrombosis and thromboembolism. The 
risk is much higher for patients with mitral prostheses, for 
patients with congestive heart failure, and for patients 
with more thrombogenic prostheses. 
 
The risk of increased bleeding during a procedure 
performed with a patient receiving antithrombotic therapy 
has to be weighed against the increased risk of 
thromboembolism caused by stopping the therapy. 
 
In patients at low risk of thrombosis, defined as those 
with a bileaflet mechanical AVR with no risk factors, it is 
recommended that Warfarin be stopped 48 to 72 hours 
before the procedure (so the INR falls to less than 1.5) 
and restarted within 24 hours after the procedure. Heparin 
is usually unnecessary [4,10]. 
 
Bridging anticoagulant therapy is recommended for the 
higher- risk individuals including those with a mechanical 
mitral or tricuspid prosthesis or those with a mechanical 
aortic prosthesis who have risk factors (table 1). The 
recommended bridging therapy is intravenous 
unfractionated heparin (UFH). Subcutaneous doses of UFH 
or low-molecular weight heparin LMWH) may also be 
considered [4,10]. 
 
The decision to provide bridging therapy requires careful 
consideration of the relative risks of thromboembolism and 
bleeding in each patient. 
 
The ACC/AHA guidelines recommend bridging therapy in 
patients with mechanical valves who require interruption 
of Warfarin therapy, as follows: 
1- In patients at high risk of thrombosis, defined as 
those with any mechanical MV replacement or a 
mechanical AVR with any risk factor (table 1), therapeutic 
doses of intravenous UFH should be started when the INR 
falls below 2.0 (typically 48 hours before surgery), 
stopped 4 to 6 hours before the procedure, restarted as 
early after surgery as bleeding stability allows, and 
continued until the INR is again therapeutic with Warfarin 
therapy. 
2 -  I n  p a t i e n t s  a t  h i g h  r i s k  of thrombosis (table 1), 
therapeutic doses of subcutaneous UFH (15 000 U every 
12 hours) or LMWH (100 U per kg every 12 hours) may be 
considered during the period of a subtherapeutic INR. 
LMWH is attractive because it is more easily used outside 
the hospital. 
 
Anticoagulation during pregnancy 
The majority of women with bioprosthetic valves do not 
require anticoagulation during pregnancy. All pregnant 
patients with mechanical prosthetic valves must receive 
continuous therapeutic anticoagulation. In women with 
mechanical valves, a detailed discussion of the advantages 
and disadvantages of the three anticoagulant options 
(Warfarin, UFH and LMWH) is indicated. 
 
Warfarin (vitamin K antagonist therapy) is an effective 
antithrombotic agent in women during pregnancy. 
Warfarin crosses the placenta and has been associated 
with an increased incidence of spontaneous abortion, 
prematurity, and stillbirth when the dose is > 5 mg/day 
[11]. 
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Warfarin is probably safe during the first 6 weeks of 
gestation, but there is a risk of embryopathy if Warfarin is 
taken between 6 and 12 weeks of gestation. Warfarin is 
also relatively safe during the second and third trimesters 
of pregnancy but must be discontinued and switched to a 
heparin compound several weeks before delivery. 
 
Several studies suggest that UFH or LMWH therapy is 
safe for the foetus [9-13]. Heparin does not cross the 
placenta and does not have the potential to cause foetal 
bleeding or teratogenicity. Thus, heparin is generally 
considered safer than Warfarin during pregnancy in terms 
of the development of embryopathy [14]. However, many 
experts questioned the efficacy of heparin in prevention of 
thromboembolic complications during pregnancy. 
Numerous case series and patient registries attest to a 
high incidence of thromboembolic complications (12% to 
24%), including fatal valve thrombosis, in high-risk 
pregnant women managed with subcutaneous UFH or 
LMWH [13-16].  
 
Low-molecular-weight heparin (LMWH) is considered a 
recommended anticoagulation option in pregnant women 
with prosthetic heart valves [17]. It has potential 
advantages over UFH during pregnancy (table 2). 
 
Pregnant patients with mechanical prosthetic valves who 
elect to stop Warfarin between weeks 6 and 12 of 
gestation should receive continuous intravenous UFH,
  dose-adjusted UFH (to maintain aPTT at least 
twice control), or dose-adjusted subcutaneous LMWH (to 
maintain the anti-Xa level between 0.7 and 1.2 units per 
ml, 4 hours after administration). In pregnant patients 
with mechanical prosthetic valves who receive Warfarin, 
the INR goal should be 3.0 (range 2.5 to 3.5). In pregnant 
women with mechanical prosthetic valves, Warfarin should 
be discontinued 2-3 weeks before planned delivery, and 
replaced with either a continuous intravenous UFH or a 
dose-adjusted LMWH [4]. 
 
The American College of Chest Physicians Conference 
on Antithrombotic and Thrombolytic Therapy [18] 
concluded that it is reasonable to use one of the following 
3 regimens:  
1- Either LMWH or UFH between 6 and 12 weeks and 
close to term only, with Warfarin used at other times;  
2- Aggressive dose-adjusted UFH throughout 
pregnancy; or  
3- Aggressive adjusted-dose LMWH throughout 
pregnancy. 
Neither Warfarin nor heparin is contraindicated in 
postpartum mothers who breast-feed. 
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